Dr. Craig Landau Appointed President and CEO Purdue Pharma L.P.
June 22 2017 - 10:06AM
Business Wire
Today, The Board of Directors of the independently associated
worldwide Purdue/Napp/Mundipharma network of companies announces
that Dr. Craig Landau is appointed President and CEO for the U.S.
operations, Purdue Pharma L.P., headquartered in Stamford,
Connecticut, with immediate effect, and will retain responsibility
for Purdue Pharma (Canada).
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20170622005723/en/
Dr. Craig Landau (Photo: Business
Wire)
CEO Mark Timney is leaving Purdue to pursue other career
opportunities. Mark’s tenure was distinguished by his ability to
set a visionary goal for the organization, his work to transform
the company to a future beyond opioids, and by developing an
outstanding talent bench. The Board and Purdue colleagues will miss
his professional strategic ability, integrity, and leadership. We
thank Mark for his service and will continue to build on the strong
foundation he laid during his time here.
Mark joined Purdue Pharma L.P. as President and Chief Executive
Officer in 2014, following an impressive career with Merck, where
he served in leadership roles for 15 years within the United States
and abroad. At Purdue, Mark diversified the company in high-need
areas and expanded beyond opioid-based pain treatments through
strategic acquisitions and creative partnerships.
During his tenure, Purdue experienced significant
diversification in the pain portfolio where the company announced a
collaboration with AnaBios to advance the research of non-opioid,
non-NSAID compounds for the treatment of chronic pain. Purdue also
acquired the innovative, non-opioid, non-NSAID treatment VM-902A
and the TrkA program in pain from VM Pharma. Additionally, a $790
million strategic research collaboration with Exicure to discover
and develop treatments for psoriasis, a strategic collaboration
with Eisai to jointly develop and commercialize the investigational
candidate Lemborexant, and an alliance with Shionogi for the joint
U.S. launch and commercialization of Symproic® (naldemedine) were
all launched under Mark’s leadership.
Craig entered the pharmaceutical industry in 1997, and two years
later joined Purdue Pharma L.P. Through his 14 years with the U.S.
organization, he would eventually become Purdue Pharma L.P.’s Chief
Medical Officer and Vice President of R&D Innovation, Clinical
and Medical Affairs. In this role and as part of the Company’s
Management Team, he and the R&D organization he led were
responsible for a number of successful health policy initiatives as
well as product registrations in the U.S. and other regions,
including Butrans®, reformulated OxyContin®, Targiniq® ER and
Hysingla® ER.
In 2013, he was appointed President and CEO of Purdue Pharma
(Canada). Over the last three years, Purdue Pharma (Canada) has
become a more diversified and stable business through the
completion of multiple strategic business development transactions,
as well as through contributions from its internal R&D
function. In addition to a portfolio of approved prescription
products for the treatment of pain, Purdue Pharma (Canada) offers
prescription treatment options for patients suffering from
attention deficit hyperactivity disorder (ADHD),
chemotherapy-induced nausea and vomiting (CINV) and ophthalmic
conditions, as well as over-the-counter (OTC) laxative,
decongestant and antiseptic products.
Craig earned his B.Sc. in Physiology and Anatomy from Cornell
University and his M.D. from Mount Sinai School of Medicine. He
completed his Anesthesiology residency at Yale University, with
specialty training in chronic pain management, obstetric and
peripheral vascular anesthesia. He is also a U.S. Army Veteran,
having concluded a distinguished 14-year career in 2005.
About Purdue Pharma L.P.
Purdue Pharma is a privately-held pharmaceutical company and is
part of a global network of independent associated companies known
for pioneering research in chronic pain and opioids with abuse
deterrent properties. The company’s leadership and employees are
committed to providing healthcare professionals, patients and
caregivers quality products and educational resources to support
their proper use. With Purdue Pharma’s expertise in drug
development, commercialization and life-cycle management, the
company is diversifying in high-need areas to expand through
strategic acquisitions and creative partnerships. For more
information, please visit www.purduepharma.com
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170622005723/en/
Media Inquiries:Purdue Pharma L.P.Bob Josephson,
203-588-7114Robert.Josephson@pharma.com